REVIEW ARTICLE – TOPICAL AZITHROMYCIN 1% FOR BLEPHARITIS Azithromycin 1% Ophthalmic Solution for Treatment of Blepharitis
نویسندگان
چکیده
Blepharitis is characterized by chronic inflammation of the lid margins, which may appear as simple hyperemia or as a true inflammation. It may occur in two forms anterior and posterior. The eyelid margins can become inflamed, irritated, and itchy when these glands produce abnormal secretions. Blepharitis is often seen in patients with acne rosacea, a generalized illness of oil glands. Anterior blepharitis is due to inflammation of the lid margin around the lashes. Seborrhoeic blepharitis is similar to dandruff of the scalp. Staphylococcal blepharitis is a result of bacterial infection of the lashes. Allergies due to reactions from mascara, contact lens solutions, and sprays, exposure to animals, environmental chemicals, or airborne allergens can also cause blepharitis.1 The single most important treatment principle is a daily routine of good eyelid hygiene ,this includes frequent scalp and face washing, using warm compresses to soak the eyelids, and doing eyelid scrubs but these treatment have very little efficacy in chronic and severe blepharitis. Antibiotic oral and ointment are also prescribed to decrease the bacterial load, other treatment modalities like artificial tear for dry eye and topical antibiotics are used in cases of severe inflammation. Topical antibiotics are recommended to decrease the bacterial load, and topical corticosteroids may help in cases of severe inflammation. Azithromycin ophthalmic solution 1% in Durasite has been proposed as a novel treatment for posterior blepharitis. 1 In this review I shall focus on Azithromycin 1% ophthalmic solution for the treatment of blepharitis based on its good anti-infective, anti-inflammatory and good tissue penetration.
منابع مشابه
Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness.
Blepharitis, one of the most commonly treated ophthalmic conditions, can also be one of the most frustrating for the managing clinician. Although this is due in part to the chronic nature of the disease, the diversity of therapeutic options and lack of definitive scientific evidence for any single course of treatment also add significant challenge to clinical management. Despite these difficult...
متن کاملAzithromycin in DuraSite® for the treatment of blepharitis
Blepharitis is a common inflammatory disease of the eyelid. Posterior blepharitis affects the posterior lamella of the eyelid and involves inflammation of the meibomian glands, whereas anterior blepharitis affects the anterior lamella of the eyelid and the eyelashes; either version can be inflammatory or infectious in nature. Each of these conditions can incite or propagate the other; anterior ...
متن کاملAzithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis.
PURPOSE To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were random...
متن کاملEfficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis.
BACKGROUND Posterior blepharitis is an eyelid disease primarily of the meibomian glands. Bacteria and chronic inflammation are contributing factors for meibomian gland disease, which leads to ocular surface and tear film alterations and chronic patient symptoms. Azithromycin 1.0% ophthalmic solution is a broad spectrum topical antibiotic with anti-inflammatory properties. The present study eval...
متن کاملReview of Azithromycin Ophthalmic 1% Solution (AzaSite®) for the Treatment of Ocular Infections
AzaSite(®) (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis. AzaSite(®) utilizes a vehicle delivery system called DuraSite(®), which stabilizes and sustains the release of azithromycin to the ocular surface, leading t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014